Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Opioid use may weaken flu shots in HIV patients, study suggests

NCT ID NCT04304768

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how opioid use affects the immune system's response to the flu vaccine in people with and without HIV. Researchers will analyze blood samples from 400 participants to measure antibody levels and immune cell activity. The goal is to understand why opioid users may have weaker immune defenses after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fluzone Quadrivalent (influenza vaccine)
What this could lead to
If successful, this could reveal how opioids impair vaccine effectiveness in people with HIV, guiding better vaccination strategies.
What could go wrong
This is an observational study focused on immune markers, not a treatment trial. Results may not lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Opioid (OP) users/non-users: 1. OP users - prescribed opioids for at least the past 90 days; or injecting opioids for at least 90 days 2. Opioid never-users in the past year Additional criteria for OP users: 1. OP use for 90 days pre-flu vaccination 2. Continued OP use for 4 weeks post flu vaccination For HIV positive participants: 1\) HIV infection, as documented by any licensed ELISA kit and confirmed by Western blot at any time prior to study entry. Participants on ART as a result of prior HIV documented infection will not be required to provide proof of diagnosis of HIV infection. Additional criteria for HIV positive participants: 1. On ART for at least 1 year with plasma pending viral load (VL) \<200 copies/mL. Occasional viral blips up to 1000 copies/ml also acceptable provided the patients are on continuing treatment 2. CD4 count available in the prior 6 months and \>200/mm3 3. Undetectable viral load (\< 200 copies/mL) For HIV negative participants: 1\) Documented negative HIV test, either by any licensed ELISA or rapid tests within the past 6 months. For all participants: 1. Individuals age 18-60 yrs . 2. No history of other immunodeficiency disorders 3. Not on steroid or other immunosuppressive/immunomodulators medications. 4. No active malignancies. 5. No contraindication to receive influenza vaccination (allergy to chicken eggs or to any other substance of the vaccine). 6. Agreeable to receive the influenza vaccination. 7. Agreeable to participate in study for a complete course of study full visits. 8. Able to provide informed consent. Exclusion Criteria: 1. Contraindication to receive influenza vaccination (allergy to chicken eggs or to any other substance of the vaccine). 2. Non-adherence to ART for HIV+ 3. Unable to provide informed consent. 4. Other comorbid conditions such as diabetes mellitus type 2 (DMT2) 5. Influenza vaccination already given during the current vaccination season.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.